| Jan 18 |
Ovid Therapeutics: Residual Value In OV935 After The OV101 Fiasco
|
| Jan 15 |
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
|
| Jan 14 |
Revisiting Ovid Therapeutics
|
| Dec 16 |
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
|
| Dec 16 |
Is OVID A Good Stock To Buy Right Now?
|
| Dec 2 |
Mid-Afternoon Market Update: Dow Edges Higher; Sequential Brands Shares Spike Higher
|
| Dec 2 |
Why Ovid Therapeutics Stock Is Imploding Today
|
| Dec 2 |
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) Investigation
|
| Dec 2 |
Benzinga's Top Upgrades, Downgrades For December 2, 2020
|
| Dec 2 |
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
|
| Dec 1 |
Ovid Therapeutics misses goal in Angelman syndrome treatment
|
| Dec 1 |
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
|
| Nov 29 |
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
|
| Nov 25 |
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
|
| Nov 23 |
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
|
| Nov 16 |
These Analysts Think Ovid Therapeutics Inc.'s (NASDAQ:OVID) Sales Are Under Threat
|
| Nov 12 |
Ovid Therapeutics EPS beats by $0.14, beats on revenue
|
| Nov 12 |
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
|
| Oct 5 |
Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
|
| Sep 30 |
Ovid's soticlestat shows positive effect in rare epilepsies
|
| Sep 26 |
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
|
| Sep 11 |
Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
|
| Aug 28 |
Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data
|
| Aug 25 |
The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout
|
| Aug 25 |
Ovid prices $50M stock offering at $8 per share
|
